Altimmune diskutieren

Altimmune, Inc. (NASDAQ: ALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.

Altimmune, Inc. (NASDAQ: ALT) had its price target lowered by analysts at B. Riley from $20.00 to $15.00. They now have a "buy" rating on the stock.

Altimmune, Inc. (NASDAQ: ALT) had its price target lowered by analysts at HC Wainwright from $50.00 to $15.00. They now have a "buy" rating on the stock.

Altimmune, Inc. (NASDAQ: ALT) had its price target lowered by analysts at B. Riley from $15.00 to $8.00. They now have a "buy" rating on the stock.

Altimmune, Inc. (NASDAQ: ALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.

Altimmune, Inc. (NASDAQ: ALT) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $20.00 price target on the stock.

Altimmune, Inc. (NASDAQ: ALT) had its price target lowered by analysts at HC Wainwright from $15.00 to $12.00. They now have a "buy" rating on the stock.

Altimmune, Inc. (NASDAQ: ALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.

Altimmune, Inc. (NASDAQ: ALT) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $25.00 price target on the stock.

Altimmune, Inc. (NASDAQ: ALT) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $20.00 price target on the stock.

Altimmune is a biotech company with a promising pipeline of obesity and cardiometabolic treatments. The recent positive data on their lead drug candidate, pemvidutide, is quite impressive. The drug demonstrated significant weight loss with a notable preservation of lean muscle mass, which sets it apart from other obesity treatments. Additionally, pemvidutide also showed the ability to reduce pro-inflammatory lipids associated with cardiovascular disease risk. This combination of weight loss and cardiovascular benefits is very compelling. While the passing of the CFO is unfortunate, the rest of the management team seems strong and capable of steering the company forward. Given the promising pipeline, I believe Altimmune is well-positioned for growth, and the current share price represents an attractive entry point for investors looking to get in on the ground floor.